ESR1 and breast cancer: Brechbuhl et al. analysed the presence of CD146‐positive and CD146‐negative CAFs in ER+ breast cancer patients' tissues and found that CD146‐negative CAFs reduce ER expression and tumour cell sensitivity to oestrogen and tamoxifen sensitivity in ER breast cancer cells.